Review
Nature Reviews Microbiology 2, 695-703 (September 2004) | doi:10.1038/nrmicro974
Focus on: Antimicrobial Strategies
Passive antibody therapy for infectious diseases
Arturo Casadevall1, Ekaterina Dadachova2 About the authors & Liise-anne Pirofski1
Abstract
Antibody-based therapies are currently undergoing a renaissance. After being developed and then largely abandoned in the twentieth century, many antibody preparations are now in clinical use. However, most of the reagents that are available target non-infectious diseases. Interest in using antibodies to treat infectious diseases is now being fuelled by the wide dissemination of drug-resistant microorganisms, the emergence of new microorganisms, the relative inefficacy of antimicrobial drugs in immunocompromised hosts and the fact that antibody-based therapies are the only means to provide immediate immunity against biological weapons. Given the need for new antimicrobial therapies and many recent technological advances in the field of immunoglobulin research, there is considerable optimism regarding renewed applications of antibody-based therapy for the prevention and treatment of infectious diseases.
- View At a Glance
Author affiliations
- Departments of Medicine (Division of Infectious Diseases) and Microbiology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
- Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Correspondence to: Arturo Casadevall1 Email: casadeva@aecom.yu.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transferNature Immunology Article (01 Oct 2001)
Science and NatureNature Letters to Editor (21 Apr 1928)
The growth and potential of human antiviral monoclonal antibody therapeuticsNature Biotechnology Research (01 Dec 2007)
See all 6 matches for Research
